Company Overview and News

 
Is SPDR Russell 1000 Momentum Focus ETF (ONEO) a Hot ETF Right Now?

2018-05-18 zacks
Making its debut on 12/02/2015, smart beta exchange traded fund SPDR Russell 1000 Momentum Focus ETF (ONEO - Free Report) provides investors broad exposure to the Large Cap ETFs category of the U.S. equity market.

 
Should JPMorgan Diversified Return U.S. Equity ETF (JPUS) Be on Your Investing Radar?

2018-05-15 zacks
If you're interested in broad exposure to the Large Cap Blend segment of the US equity market, look no further than the JPMorgan Diversified Return U.S. Equity ETF (JPUS - Free Report) , a passively managed exchange traded fund launched on 09/29/2015.

 
Week 20 Breakout Forecast: Short-Term Picks To Give You An Edge

2018-05-14 seekingalpha
Publishing 2 of the 8 new Week 20 breakout stocks that are available only to subscribers with better than 10% short-term upside potential.

 
Big U.S. Stocks' Q1'18 Fundamentals

2018-05-12 seekingalpha
The big US stocks’ latest quarterly results proved amazingly good. Sales and profits both rocketed higher as extreme stock-market optimism and big-corporate-tax-cut hopes fueled massive spending.

 
U.S. Weekly FundFlows Insight Report: Weekly Equity Fund Flows Turn Negative Despite The Up Market

2018-05-11 seekingalpha
For the third week in a row, investors were net purchasers of fund assets (including those of conventional funds and ETFs), taking in a little more than $8.2 billion. Despite market gains during the week, fund investors were net redeemers of equity funds (-$231 million) while being net purchasers of money market funds (+$8.2 billion), municipal bond funds (+$167 million), and taxable bond funds (+$86 million) for the fund-flows week ended May 9, 2018.

 
Is iShares Core Conservative Allocation ETF (AOK) a Hot ETF Right Now?

2018-05-08 zacks
Launched on 11/04/2008, the iShares Core Conservative Allocation ETF (AOK - Free Report) is a smart beta exchange traded fund offering broad exposure to the Total Portfolio ETFs category of the U.S. equity market.

 
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?

2018-05-02 zacks
Looking for broad exposure to the Large Cap Blend segment of the US equity market? You should consider the SPDR Russell 1000 Low Volatility Focus ETF (ONEV - Free Report) , a passively managed exchange traded fund launched on 12/02/2015.

 
ETF Asset Report for April 2018: Bonds Top

2018-04-30 zacks
The month of April was mixed with earnings showing promise and broader markets returning decent returns despite rising yields and trade tensions. Oil has been on an uptrend. Overall, SPDR S&P 500 ETF (SPY - Free Report) gained about 3.5% in a month’s time (as of Apr 27, 2018), SPDR Dow Jones Industrial Average ETF (DIA - Free Report) rose 2.9% while Nasdaq-100-bsed ETF PowerShares QQQ ETF (QQQ - Free Report) jumped 4.

 
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

2018-04-30 zacks
Looking for broad exposure to the Large Cap Blend segment of the US equity market? You should consider the First Trust Capital Strength ETF (FTCS - Free Report) , a passively managed exchange traded fund launched on 07/06/2006.

1
Should SPDR Russell 1000 Momentum Focus ETF (ONEO) Be on Your Investing Radar?

2018-04-27 zacks
Launched on 12/02/2015, the SPDR Russell 1000 Momentum Focus ETF (ONEO - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Blend segment of the US equity market.

 
U.S. Weekly FundFlows Insight Report: Fund Flows Remain Positive For The Week In Spite Of Market Declines And Rising Yields

2018-04-27 seekingalpha
For the second week in three, investors were net purchasers of fund assets (including those of conventional funds and ETFs), injecting a little more than $8.0 billion. In spite of market declines and rising yields, fund investors were net purchasers of equity funds (+$3.5 billion), money market funds (+$3.3 billion), taxable bond funds (+$0.9 billion), and municipal bond funds (+$229 million) for the fund flows week ended April 25, 2018.

 
Should John Hancock Multifactor Large Cap ETF (JHML) Be on Your Investing Radar?

2018-04-23 zacks
The John Hancock Multifactor Large Cap ETF (JHML - Free Report) was launched on 09/28/2015, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Blend segment of the US equity market.

 
SPY And The Cost Of Liquidity

2018-04-20 seekingalpha
The SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is the oldest U.S. ETF. Having launched in 1993, SPY recently celebrated its 25th birthday and it remains the largest ETF. SPY’s $259 billion in assets are more than $100 billion greater than that of its closest rival, the iShares Core S&P 500 ETF (NYSEARCA:IVV), which has $144 billion. A large asset base helps an index fund track its index with precision. SPY also offers tremendous liquidity with nearly $25 billion in daily dollar volume compared to $1.

 
Should JPMorgan Diversified Return U.S. Equity ETF (JPUS) Be on Your Investing Radar?

2018-04-20 zacks
If you're interested in broad exposure to the Large Cap Blend segment of the US equity market, look no further than the JPMorgan Diversified Return U.S. Equity ETF (JPUS - Free Report) , a passively managed exchange traded fund launched on 09/29/2015.

1
Should PowerShares Russell 1000 Equal Weight Portfolio (EQAL) Be on Your Investing Radar?

2018-04-16 zacks
If you're interested in broad exposure to the Large Cap Blend segment of the US equity market, look no further than the PowerShares Russell 1000 Equal Weight Portfolio (EQAL - Free Report) , a passively managed exchange traded fund launched on 12/23/2014.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 464287200